Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Password Reset

Email Address

Search for:

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on gastrointestinal and related diseases that are eligible for FDA Fast-tracking. We expect to file our first IND in late 2021 jointly with a major institution in pancreatic cancer/cachexia. ***

Recent News

Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
In The News: Supertrends
Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.

JOIN OUR MAILING LIST

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact